Accueil > Actualité
Actualite financiere : Actualite bourse

Roche: promising studies for faricimab

( - Roche announced late yesterday the publication in "The Lancet" of two papers reporting results from four one-year phase III studies of faricimab as a potential treatment for wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).

All four studies - which enrolled over 3,000 people in total - met their primary endpoints, showing that people treated with faricimab, with at least one administration every four months, achieved non-inferior vision gains to those treated with aflibercept administered every two months.

To date, standard of care treatment requires eye injections once a month.

Copyright (c) 2022 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.